Related Experiment Video
Updated: Jun 16, 2026

DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data
Published on: December 15, 2023
Decoding disease and therapy through multiomics integration and systems analysis
Mano Joseph Mathew1,2, Joyal Mathew3, Ripsy Merrin Chacko1,4,5,6
1Laboratoire Génomique, Bioinformatique et Chimie Moléculaire, EA7528, Conservatoire National des Arts et Métiers, HESAM Université, 2 Rue Conté, 75003 Paris, Ile de France, France.
None:
Computational multiomics methods are based on machine learning methods, and are primarily used for classifying patients into subtypes, discovering novel biomarkers, drug repurposing, and advancing precision medicine. Advances in high-throughput technologies have enabled comprehensive profiling of multiple molecular layers, resulting in the emergence of multiomics approaches for a more accurate understanding of disease mechanisms, therapeutic targets, and biological heterogeneity. This review examines current applications of multiomics in oncology, ageing, and immune-mediated diseases, highlighting the strengths and challenges of integrative models in understanding disease mechanisms, identifying biomarkers, and guiding precision therapies. Integration strategies, from early to late fusion and horizontal to vertical frameworks, are also examined alongside recent advances in computational platforms and preprocessing techniques.
Related Concept Videos
Genomics
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenomics: Identification of New Drug Targets
